Volition Hosts KOL Roundtable on Sepsis

Professor Annane, said: "The need for improvements in sepsis management and patient outcomes is clear. Sepsis kills over 11 million people worldwide each year, and approximately half of those who survive the disease are left with devastating, long-term physical and psychological effects. Early detection and management of sepsis has the potential to reduce mortality and improve the quality of life of survivors.

"We brought together experts in sepsis from across the globe to share research findings from several large independent studies, and consider how Volition's Nu.Q® NETs technology could be introduced in clinical practice.

"It was clear from our roundtable discussion and confidential data review that Nu.Q® NETs has the potential to predict organ failure, for example, acute kidney injury in patients with infection and therefore could be used to enhance sepsis management."

Nu.Q® NETs, Volition's nucleosome quantification technology, is a simple, low-cost, accessible test that quantifies an individual's level of circulating H3.1 nucleosomes in the bloodstream, a surrogate marker for Neutrophil Extracellular Traps (NETs). Although NETs play a critical role in our normal immune response, elevated levels of NETs can lead to tissue damage, and in severe cases, sepsis, organ failure and death.

Dr Andrew Retter, Chief Medical Officer at Volition, said: "Volition is collaborating closely with KOLs and centers of excellence worldwide, and we are delighted to have hosted such an esteemed roundtable event. With a range of publications pending, we look forward to sharing latest findings at our upcoming satellite symposium, taking place at ESICM in Barcelona on Monday 7^th October 2024." 

Chaired by Professor Djillali Annane Volition's KOL event comprised:

• Professor Derek Angus, Professor and Chair of the Critical Care Medicine Department at the University of Pittsburgh. Professor Angus is a world-renowned clinical, translational and health services researcher. (Partial attendance; virtual)
• Professor Michael Bauer, Professor and Chair of the Department of Anaesthesiology and Intensive Care Medicine at Jena University Hospital, Germany.
• Dr. Lieuwe Bos is Principal Investigator within the Intensive Care department at Amsterdam UMC. He is also an associate professor at the University of Amsterdam. (Partial attendance)
• Professor Luc de Chaisemartin is Professor of Immunology at Paris-Cité University, and Head of the Biological Immunology Department at Bichat Hospital, Paris.
• Dr. Charles Dehout is an attending physician at Erasmus Hospital in Brussels, specializing in internal medicine and intensive care.
• Professor Evangelos J. Giamarellos-Bourboulis, National and Kapodistrian University of Athens, Greece and Chair of the European Sepsis Alliance.
• Dr. Caroline  Neumann is Caroline Neumann is a Senior Consultant in Intensive Care Medicine at Jena University Hospital, Germany.
• Dr. Andrew Retter, Clinical Lead in Critical Care Medicine, ECMO and Thrombosis, and Chief Medical Officer at Volition.
• Professor Mervyn Singer OBE, University College London, UK. Co-chair of the Sepsis-3 Definitions International Task Force; past-chair, International Sepsis Forum; Sepsis Topic Adviser to NICE; Emeritus NIHR Senior Investigator.

Notes

• Sepsis arises when the body's response to an infection injures its own tissues and organs. It may lead to shock, multi-organ failure, and death – especially if not recognized early and treated promptly. (Global Sepsis Alliance - World Sepsis Day website)
• Sepsis is the number one cause of death in hospitals worldwide and accounts for at least 11 million deaths per year.
• September is Sepsis Awareness Month and World Sepsis Day takes place on Friday 13^th September 2024.

About Volition

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients, but also improve their quality of life.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore. 

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

Media Enquiries:

Louise Batchelor/Debra Daglish, Volition, [email protected] +44 (0)7557 774620

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to the timing, completion, success and delivery of data from clinical studies, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this press release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. 

Photo: https://mma.prnewswire.com/media/2502647/VolitionRx.jpg

SOURCE VolitionRx Limited